Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate

Scientia Pharmaceutica

Volumn 78, Issue 4, 2010, Pages 959-976

  Gupta, Swati ^a,b   Vyas, Suresh P ^b  

^a ISF COLLEGE OF PHARMACY   (India)

^b DR H S GOUR UNIVERSITY   (India)

Author keywords

Glaucoma; In situ gelation; Ocular delivery; Sustained delivery; Timolol maleate

Indexed keywords

CARBOMER; CHITOSAN; GLUCOMOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; MALE; NONHUMAN; PH MEASUREMENT; RABBIT;

EID: 78650227405     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1001-06     Document Type: Article

References (26)

1. Sieg JW, Robinson JR. Mechanistic studies of transcorneal permeation of Pilocarpine. J Pharm Sci. 1976; 65: 1816-1822. doi:10.1002/jps.2600651230
2. Lee VHL. Precorneal, corneal and postcorneal factors. In: Ophthalmic Drug Delivery Systems, Drug and the Pharmaceutical Sciences. AK Mitra (ed.)Volume 58, New York, Basel, and Hong Kong: Marcel Dekker Inc, 1993: 59-81.
3. Chein YW, Cabana BE, Mares SE. Ocular controlled-release drug administration. In: Novel Drug Delivery Systems: Fundamentals, Developmental Concepts, Biomedical Assessments, Drugs and the Pharmaceutical Sciences. Chein YW. (ed.), Volume 14, New York and Basel: Marcel Dekker Inc, 1982: 13-50.
4. Schoenwald RD, Smolen VF. Drug absorption analysis from pharmacological Data II: Transcorneal biophasic availability of tropicamide. J Pharm Sci. 1971; 60: 1039-1045. doi:10.1002/jps.2600600708
5. Lee VHL, Robinson JR. Topical ocular drug delivery: Recent developments and future challenges. J Ocular Pharmacol. 1986; 2: 67-108. doi:10.1089/jop.1986.2.67
6. Lee VHL. New directions in the optimization of ocular drug delivery. J Ocular Pharmacol. 1990; 6: 157-164. doi:10.1089/jop.1990.6.157
7. Munroe WP, Rindone JP, Kershner RM. Systemic side effects associated with the ophthalmic administration of timolol. Drug Intell Clin Pharm. 1985; 19: 85-89. PMid:3882377
8. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol. 1993; 37: 435-456. doi:10.1016/0039-6257(93)90141-S
9. Nelson WL, Fraunfelder FT, Sills JM Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution. Am J Ophthalmol. 1986; 102: 606-611. PMid:3777080
10. Davies NM, Farr SJ, Hadgraft J, Kellaway IW. Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions. Pharm Res. 1991; 8: 1039-1043. doi:10.1023/A:1015813225804
11. Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD, Leroux JC, Atkinson BL, Binette F, Selmani A. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials. 2000; 21: 2155-2161. doi:10.1016/S0142 9612(00)00116-2
12. Schoenwald RD, Ward RL, DeSantis LM, Roehrs RE. Influence of high viscosity vehicles on miotic effect of pilocarpine. J Pharm Sci. 1978; 67: 1280-1283. doi:10.1002/jps.2600670923
13. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Rel. 2001; 73: 205-211. doi:10.1016/S0168-3659(01)00279-6
14. Kumar S, Himmelstein KJ. Modification of in situ gelling behavior of carbopol solutions by hydroxypropyl methylcellulose. J Pharm Sci. 1995; 84: 344-348. doi:10.1002/jps.2600840315
15. Miller SC, Donovan MD. Effect of Poloxamer 407 gel on the mitotic activity of pilocarpine nitrate in rabbits. Int J Pharm. 1982; 12: 147-152. doi:10.1016/0378-5173(82)90114-4
16. Vadnere M, Amidon G, Lindenbaum S, Haslam JL. Thermodynamic studies on the gel-sol transition of some pluronic polyols. Int J Pharm. 1984; 22: 207-218. doi:10.1016/0378-5173(84)90022-X
17. Gurny R, Boye T, Ibrahim H. Ocular therapy with nanoparticulate systems for controlled drug delivery. J Control Rel. 1985; 2: 353-361. doi:10.1016/0168-3659(85)90057-4
18. ®: A novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm. 1989;57: 163-168. doi:10.1016/0378-5173(89)90305-0
19. Joshi A, Ding S, Himmelstein KJ. Reversible gelation composition and methods of use. U.S. Patent 5, 252, 318, October 12, 1993.
20. Cohen S, Lobel F, Trevgoda A, Peled Y. A novel in situ-forming ophthalmic drug delivery systems from alginates undergoing gelation in the eye. J Control Rel. 1997; 44: 201-208. doi:10.1016/S0168-3659(96)01523-4
21. New RRC, editor. Introduction and preparation of liposomes In: Liposomes: A practical approach. R.R.C. New (ed); Oxford: Oxford University Press, 1990: 1-104.
22. Sanzgiri YD, Maschi S, Crescenzi V, Callegaro L, Topp EM, Stella VJ. Gellan based systems for ophthalmic sustained delivery of methylprednisolone. J Control Rel. 1993; 26: 195-201. doi:10.1016/0168-3659(93)90186-9
23. Bonomi L, Perfetti S, Noya E, Bellucci R, Tomazzoli L. Experimental corticosteroid ocular hypertension in the rabbit. Graefes Arch. Klin Exp Ophthalmol. 1978; 209: 73-82. doi:10.1007/BF00407840
24. rd ed. Philadelphia, London: Lea and Febiger, 1995: 469-470.
25. Kubota K, Yamada T, Ogura A, Ishizaki T. A novel differentiation method of vehicle models for topically applied drugs: Application to a therapeutic timolol patch. J Pharm Sci. 1990; 79: 179-184. doi:10.1002/jps.2600790220
26. Kubota K, Koyama E, Yasuda K. Skin irritation induced by topically applied timolol. Br J Clin Pharmacol. 1991; 31: 471-475. PMid:2049257